IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Effect of Glutamine on Intestinal Permeability in Crohn's Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Crohn's Disease | Dietary Supplement: Glutamine Dietary Supplement: Whey protein | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Effect of Glutamine Supplementation on the Structure and Function of the Mucosa of Small Intestine in Crohn's Disease: A Randomized Controlled Trial |
- Improvement in intestinal permeability after glutamine supplementation [ Time Frame: Baseline and after two months of intervention ]
- Change in small intestinal morphology after glutamine supplementation [ Time Frame: Baseline and after two months of intervention ]
| Enrollment: | 30 |
| Study Start Date: | November 2005 |
| Study Completion Date: | November 2008 |
| Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Glutamine
Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
|
Dietary Supplement: Glutamine
Glutamine group : Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months. Other Name: L-Glutamine
|
|
Placebo Comparator: Whey Protein
Whey Protein: Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months. |
Dietary Supplement: Glutamine
Glutamine group : Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months. Other Name: L-Glutamine
Dietary Supplement: Whey protein
Whey protein group: Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months. Other Name: Whey Protein Concentrate
|
Detailed Description:
Glutamine is the most abundant amino acid in the body constituting 50% to 60% of total free amino acid pool in muscle and 20% in plasma. Recently it has been reclassified as a conditionally essential amino acid due to body's inability to synthesize sufficient amount under stressful conditions like trauma and sepsis. It is an essential fuel for fibroblasts, lymphocytes and enterocytes. It plays an important role in nitrogen balance and an integral role in glucose regulation and also in acid base homeostasis. It is an essential ingredient for glutathione, an important antioxidant. During the last decade a number of experimental and clinical studies, by using enteral and parenteral glutamine supplements, have shown its beneficial role in conditions like sepsis and infection, elective surgery and accidental injury, catabolic state, fetal and critically ill low birth weight neonates and cancer. A few experimental and clinical studies have also shown its positive role in inflammatory bowel disease, which is attributed to the effect of glutamine on intestinal permeability, growth of enterocytes, enhancement of gut immunity and glutathione synthesis. So far there is hardly any well-planned randomized trial of enteral glutamine supplements in Crohn's disease. Hence this study is planned to evaluate effect of enteral glutamine supplements on structure and function of intestine in patients with Crohn's disease.
Diagnosed cases of Crohn's Disease attending Gastroenterology OPD or admitted in ward at AIIMS will be randomized into two groups, glutamine and whey protein group. The parameters for intestinal function and structure tested will be, permeability, villous height, plasma glutamine and D-xylose absorption at the base line and at the end of the intervention. As per the available data improvement is expected in both structure and function of the intestine, which will be an important contribution in the management of this chronic disease.
Eligibility| Ages Eligible for Study: | 15 Years to 60 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All the consecutive patients with Crohn's disease in the remission phase with an abnormal intestinal permeability (IP)
Exclusion Criteria:
- Patients in the active phase of the disease i.e. CDAI score >150
- Patients with a normal intestinal permeability i.e. LMR < 0.0373
- Patients already taking a high protein nutritional supplement
- Patients with other associated systemic diseases like chronic liver disease, chronic kidney disease, diabetes mellitus, malignancy
- Patients with a special physiologic condition i.e., pregnancy or lactation.
- Patients lesser than 15 years (pediatric group) and more than 60 years of age (elderly patients)
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00838149
| India | |
| All India Institute of Medical Sciences | |
| New Delhi, India, 110029 | |
| Principal Investigator: | Yogendra K Joshi, M.D., PhD. | All India Institute of Medical Sciences, New Delhi |
More Information
| Responsible Party: | Prof. Y K Joshi, All India Institute of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT00838149 History of Changes |
| Other Study ID Numbers: |
I458 |
| Study First Received: | February 5, 2009 |
| Last Updated: | February 5, 2009 |
Additional relevant MeSH terms:
|
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis |
Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases |
ClinicalTrials.gov processed this record on August 18, 2017